Marcelo Murillo/iStock by way of Getty Pictures
Rubius (NASDAQ:RUBY) had a 24% brief curiosity As quickly as I coated it in March. The worth was above $6. People who briefed the inventory Inside the Meantime made An excellent deal Of money, as a Outcome of after The agency launched further knowledge from RTX-240 at AACR in April, the inventory fell Greater than 80%. Right now It is a penny inventory, buying and promoting at 79 cents. It has solely been 3 months. Such is the unppurpleictable world of biotech.
Rubius was once a extremely engaging inventory. It wasn’t engaging Because of strong fundamentals or strong knowledge, however as a Outcome of its fobeneaths are world well-known scientists. The agency was constructed “upon the discoveries of Professors Harvey Lodish and Hidde Ploegh of the Whitehead Institute for Biomedical Evaluation at MIT and the research and discoverings of Flagship Pioneering’s VentureLabs.” Professor Lodish is a extremely regarded biologist beneath whose tutelage a quantity of scientists have gained the Nobel Prize. So as that was the preliminary attraction of Rubius.
Neverthemuch less, The agency has singularly Did not stay As a lot as its promise. After an preliminary spurt of respectable knowledge, Rubius has failed miserably, As quickly as extra and again, To level out constructive knowledge. Their first molecule was RTX-314, and it was An …….